AG˹ٷ

STOCK TITAN

[Form 4] Triumph Financial, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 filing for UnitedHealth Group (UNH) dated 07/02/2025 discloses routine quarterly equity compensation to non-employee director Paul R. Garcia.

  • Transactions (07/01/2025): 173 deferred stock units (immediately vested, must be held until board service ends) and 96 shares of common stock, both awarded at $0 cost.
  • Post-transaction ownership: 2,750 common shares held directly; 2,146 shares in a revocable trust; 45 and 55 shares in two additional trusts, for a total indirect holding of 2,246 shares.
  • No derivative securities were acquired or disposed of; the filing cites the awards as regular quarterly director compensation, not incentive-based or market purchases.

The filing is administrative in nature, with no impact on company operations, capital structure, or insider sentiment beyond customary board compensation.

Deposito del Modulo 4 per UnitedHealth Group (UNH) datato 02/07/2025 rivela la consueta compensazione azionaria trimestrale per il direttore non esecutivo Paul R. Garcia.

  • Transazioni (01/07/2025): 173 unità azionarie differite (immediatamente maturate, devono essere detenute fino alla fine del mandato nel consiglio) e 96 azioni ordinarie, entrambe assegnate a costo $0.
  • Possesso post-transazione: 2.750 azioni ordinarie detenute direttamente; 2.146 azioni in un trust revocabile; 45 e 55 azioni in due trust aggiuntivi, per un totale di 2.246 azioni detenute indirettamente.
  • Non sono stati acquisiti né ceduti titoli derivati; il deposito indica le assegnazioni come compensazione regolare trimestrale per il direttore, non basata su incentivi o acquisti di mercato.

Il deposito ha natura amministrativa, con nessun impatto sulle operazioni aziendali, sulla struttura del capitale o sul sentiment interno oltre la consueta compensazione del consiglio.

Presentación del Formulario 4 para UnitedHealth Group (UNH) fechada el 02/07/2025 revela la compensación trimestral rutinaria en acciones para el director no ejecutivo Paul R. Garcia.

  • Transacciones (01/07/2025): 173 unidades de acciones diferidas (adquiridas inmediatamente, deben mantenerse hasta que termine el servicio en la junta) y 96 acciones comunes, ambas otorgadas a costo $0.
  • Propiedad tras la transacción: 2,750 acciones comunes en propiedad directa; 2,146 acciones en un fideicomiso revocable; 45 y 55 acciones en dos fideicomisos adicionales, sumando un total de 2,246 acciones en propiedad indirecta.
  • No se adquirieron ni dispusieron valores derivados; la presentación señala que las asignaciones son compensación trimestral regular para directores, no basadas en incentivos ni compras en mercado.

La presentación es de naturaleza administrativa, sin impacto en las operaciones de la empresa, estructura de capital o sentimiento interno más allá de la compensación habitual de la junta.

UnitedHealth Group (UNH)� 2025� 7� 2일자 Form 4 제출�� 비임� 이사 Paul R. Garcia� 대� 정기 분기� 주식 보상� 공개합니�.

  • 거래 내역 (2025� 7� 1�): 173개의 이연 주식 단위(즉시 취득, 이사� 임기 종료 시까지 보유해야 �) � 96주의 보통주를 각각 무상으로 받았습니�.
  • 거래 � 보유 현황: 직접 보유� 보통� 2,750�; 취소 가능한 신탁� 2,146�; 추가 � 신탁� 각각 45주와 55�, � 2,246주의 간접 보유.
  • 파생 증권은 취득하거� 처분하지 않았으며, 제출서에� 해당 보상� 인센티브 기반이나 시장 구매가 아닌 정규 분기� 이사 보상으로 명시되어 있습니다.

� 제출서는 행정적인 성격이며, 회사 운영, 자본 구조 또는 내부� 심리� 관� 관례적인 이사� 보상� 넘어서는 영향은 없습니다.

Dépôt du formulaire 4 pour UnitedHealth Group (UNH) daté du 02/07/2025 révèle la rémunération trimestrielle habituelle en actions pour le directeur non salarié Paul R. Garcia.

  • Transactions (01/07/2025) : 173 unités d'actions différées (acquises immédiatement, doivent être conservées jusqu'à la fin du mandat au conseil) et 96 actions ordinaires, toutes deux attribuées à coût nul.
  • Possession après transaction : 2 750 actions ordinaires détenues directement ; 2 146 actions dans un trust révocable ; 45 et 55 actions dans deux trusts supplémentaires, totalisant 2 246 actions détenues indirectement.
  • Aucun titre dérivé n'a été acquis ou cédé ; le dépôt précise que ces attributions correspondent à une rémunération trimestrielle régulière des administrateurs, non basée sur des incitations ou des achats sur le marché.

Le dépôt est de nature administrative, sans impact sur les opérations de l'entreprise, la structure du capital ou le sentiment des initiés au-delà de la rémunération habituelle du conseil.

Formular 4 Einreichung für UnitedHealth Group (UNH) vom 02.07.2025 offenbart die routinemäßige vierteljährliche Aktienvergütung für den nicht geschäftsführenden Direktor Paul R. Garcia.

  • Transaktionen (01.07.2025): 173 aufgeschobene Aktienanteile (sofort unverfallbar, müssen bis zum Ende der Vorstandstätigkeit gehalten werden) und 96 Stammaktien, beide ohne Kosten ($0) zugeteilt.
  • Eigentum nach der Transaktion: 2.750 Stammaktien direkt gehalten; 2.146 Aktien in einem widerruflichen Trust; 45 und 55 Aktien in zwei weiteren Trusts, insgesamt 2.246 Aktien indirekt gehalten.
  • Keine Derivate wurden erworben oder veräußert; die Einreichung beschreibt die Zuteilungen als reguläre vierteljährliche Direktorenvergütung, nicht als leistungsabhängig oder Marktkäufe.

Die Einreichung ist administrativer Natur und hat keinen Einfluss auf den Geschäftsbetrieb, die Kapitalstruktur oder das Insider-Sentiment über die übliche Vorstandsvergütung hinaus.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine director equity grant; neutral for valuation.

The reported acquisitions are standard board compensation—non-cash and immaterial relative to UNH’s 930 million shares outstanding. The director’s aggregate direct stake (�0.0003%) remains negligible, offering no meaningful signal of insider conviction or strategy shift. No derivatives, sales, or large block moves were disclosed, and there is no indication of upcoming corporate events. Consequently, the filing should be viewed as housekeeping rather than a catalyst.

TL;DR: Confirms UNH’s standard board pay structure; no red flags.

The grant aligns with prevailing S&P 500 director pay practice of quarterly stock/DSU awards to foster alignment with shareholders. Mandatory deferral of DSUs until board departure supports long-term oversight. No unusual acceleration clauses or special awards appear, indicating consistent, transparent governance. The filing poses no governance concerns and is non-impactful to investors.

Deposito del Modulo 4 per UnitedHealth Group (UNH) datato 02/07/2025 rivela la consueta compensazione azionaria trimestrale per il direttore non esecutivo Paul R. Garcia.

  • Transazioni (01/07/2025): 173 unità azionarie differite (immediatamente maturate, devono essere detenute fino alla fine del mandato nel consiglio) e 96 azioni ordinarie, entrambe assegnate a costo $0.
  • Possesso post-transazione: 2.750 azioni ordinarie detenute direttamente; 2.146 azioni in un trust revocabile; 45 e 55 azioni in due trust aggiuntivi, per un totale di 2.246 azioni detenute indirettamente.
  • Non sono stati acquisiti né ceduti titoli derivati; il deposito indica le assegnazioni come compensazione regolare trimestrale per il direttore, non basata su incentivi o acquisti di mercato.

Il deposito ha natura amministrativa, con nessun impatto sulle operazioni aziendali, sulla struttura del capitale o sul sentiment interno oltre la consueta compensazione del consiglio.

Presentación del Formulario 4 para UnitedHealth Group (UNH) fechada el 02/07/2025 revela la compensación trimestral rutinaria en acciones para el director no ejecutivo Paul R. Garcia.

  • Transacciones (01/07/2025): 173 unidades de acciones diferidas (adquiridas inmediatamente, deben mantenerse hasta que termine el servicio en la junta) y 96 acciones comunes, ambas otorgadas a costo $0.
  • Propiedad tras la transacción: 2,750 acciones comunes en propiedad directa; 2,146 acciones en un fideicomiso revocable; 45 y 55 acciones en dos fideicomisos adicionales, sumando un total de 2,246 acciones en propiedad indirecta.
  • No se adquirieron ni dispusieron valores derivados; la presentación señala que las asignaciones son compensación trimestral regular para directores, no basadas en incentivos ni compras en mercado.

La presentación es de naturaleza administrativa, sin impacto en las operaciones de la empresa, estructura de capital o sentimiento interno más allá de la compensación habitual de la junta.

UnitedHealth Group (UNH)� 2025� 7� 2일자 Form 4 제출�� 비임� 이사 Paul R. Garcia� 대� 정기 분기� 주식 보상� 공개합니�.

  • 거래 내역 (2025� 7� 1�): 173개의 이연 주식 단위(즉시 취득, 이사� 임기 종료 시까지 보유해야 �) � 96주의 보통주를 각각 무상으로 받았습니�.
  • 거래 � 보유 현황: 직접 보유� 보통� 2,750�; 취소 가능한 신탁� 2,146�; 추가 � 신탁� 각각 45주와 55�, � 2,246주의 간접 보유.
  • 파생 증권은 취득하거� 처분하지 않았으며, 제출서에� 해당 보상� 인센티브 기반이나 시장 구매가 아닌 정규 분기� 이사 보상으로 명시되어 있습니다.

� 제출서는 행정적인 성격이며, 회사 운영, 자본 구조 또는 내부� 심리� 관� 관례적인 이사� 보상� 넘어서는 영향은 없습니다.

Dépôt du formulaire 4 pour UnitedHealth Group (UNH) daté du 02/07/2025 révèle la rémunération trimestrielle habituelle en actions pour le directeur non salarié Paul R. Garcia.

  • Transactions (01/07/2025) : 173 unités d'actions différées (acquises immédiatement, doivent être conservées jusqu'à la fin du mandat au conseil) et 96 actions ordinaires, toutes deux attribuées à coût nul.
  • Possession après transaction : 2 750 actions ordinaires détenues directement ; 2 146 actions dans un trust révocable ; 45 et 55 actions dans deux trusts supplémentaires, totalisant 2 246 actions détenues indirectement.
  • Aucun titre dérivé n'a été acquis ou cédé ; le dépôt précise que ces attributions correspondent à une rémunération trimestrielle régulière des administrateurs, non basée sur des incitations ou des achats sur le marché.

Le dépôt est de nature administrative, sans impact sur les opérations de l'entreprise, la structure du capital ou le sentiment des initiés au-delà de la rémunération habituelle du conseil.

Formular 4 Einreichung für UnitedHealth Group (UNH) vom 02.07.2025 offenbart die routinemäßige vierteljährliche Aktienvergütung für den nicht geschäftsführenden Direktor Paul R. Garcia.

  • Transaktionen (01.07.2025): 173 aufgeschobene Aktienanteile (sofort unverfallbar, müssen bis zum Ende der Vorstandstätigkeit gehalten werden) und 96 Stammaktien, beide ohne Kosten ($0) zugeteilt.
  • Eigentum nach der Transaktion: 2.750 Stammaktien direkt gehalten; 2.146 Aktien in einem widerruflichen Trust; 45 und 55 Aktien in zwei weiteren Trusts, insgesamt 2.246 Aktien indirekt gehalten.
  • Keine Derivate wurden erworben oder veräußert; die Einreichung beschreibt die Zuteilungen als reguläre vierteljährliche Direktorenvergütung, nicht als leistungsabhängig oder Marktkäufe.

Die Einreichung ist administrativer Natur und hat keinen Einfluss auf den Geschäftsbetrieb, die Kapitalstruktur oder das Insider-Sentiment über die übliche Vorstandsvergütung hinaus.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Deadman Davis R

(Last) (First) (Middle)
12700 PARK CENTRAL DRIVE
SUITE 1700

(Street)
DALLAS TX 75251

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Triumph Financial, Inc. [ TFIN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/01/2025 A 613(1) A $0(1) 10,833 D
Depository Shares(2) 26,500 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares of Common Stock of Issuer granted to the reporting person under Issuer's 2014 Omnibus Incentive Plan. All of such shares were fully vested as of the date of grant.
2. Each Depository Shares represents a 1/40th interest in a share of the Issuer's 7.125% Series C Fixed Rate Non-Cumulative Perpetual Preferred Stock, par value $0.01 per share.
Remarks:
/s/ Adam D. Nelson, Attorney-in-fact 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many UnitedHealth Group shares did Paul R. Garcia acquire on 07/01/2025?

He received 96 shares of common stock and 173 deferred stock units as part of quarterly board compensation.

What is Paul R. Garcia’s total direct ownership in UNH after the transaction?

Following the award, he directly holds 2,750 common shares of UnitedHealth Group.

Are the deferred stock units (DSUs) immediately vested?

Yes. The DSUs vest immediately but must be held until the director’s service on the board ends.

Did the filing disclose any insider sales or derivative transactions?

No. The Form 4 reports only acquisitions of stock and DSUs; no sales or derivative activity were reported.

Does this Form 4 filing affect UnitedHealth Group’s share count?

No. The awards are sourced from the company’s existing equity compensation plan and do not materially alter the total shares outstanding.
Triumph Financial Inc

NASDAQ:TFIN

TFIN Rankings

TFIN Latest News

TFIN Latest SEC Filings

TFIN Stock Data

1.49B
22.36M
5.5%
93.76%
7.32%
Banks - Regional
State Commercial Banks
United States
DALLAS